Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.11
NYSE:Q's Cash-to-Debt is ranked lower than
90% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NYSE:Q: 0.11 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:Q' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.38 Max: N/A
Current: 0.11
Equity-to-Asset 0.36
NYSE:Q's Equity-to-Asset is ranked lower than
72% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:Q: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:Q' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.55  Med: -0.19 Max: 0.41
Current: 0.36
-0.55
0.41
Interest Coverage 3.27
NYSE:Q's Interest Coverage is ranked lower than
83% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. NYSE:Q: 3.27 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:Q' s Interest Coverage Range Over the Past 10 Years
Min: 2.79  Med: 3.74 Max: 6.4
Current: 3.27
2.79
6.4
Piotroski F-Score: 5
Altman Z-Score: 1.28
Beneish M-Score: -1.30
WACC vs ROIC
4.92%
-1.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 8.19
NYSE:Q's Operating Margin % is ranked higher than
65% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NYSE:Q: 8.19 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:Q' s Operating Margin % Range Over the Past 10 Years
Min: 7.98  Med: 9.33 Max: 11.26
Current: 8.19
7.98
11.26
Net Margin % 1.07
NYSE:Q's Net Margin % is ranked higher than
53% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NYSE:Q: 1.07 )
Ranked among companies with meaningful Net Margin % only.
NYSE:Q' s Net Margin % Range Over the Past 10 Years
Min: 1.07  Med: 4.44 Max: 6.75
Current: 1.07
1.07
6.75
ROE % 2.74
NYSE:Q's ROE % is ranked higher than
60% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NYSE:Q: 2.74 )
Ranked among companies with meaningful ROE % only.
NYSE:Q' s ROE % Range Over the Past 10 Years
Min: 2.74  Med: 2.85 Max: 2.85
Current: 2.74
2.74
2.85
ROA % 0.76
NYSE:Q's ROA % is ranked higher than
58% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NYSE:Q: 0.76 )
Ranked among companies with meaningful ROA % only.
NYSE:Q' s ROA % Range Over the Past 10 Years
Min: 0.76  Med: 9.43 Max: 20.82
Current: 0.76
0.76
20.82
ROC (Joel Greenblatt) % 221.96
NYSE:Q's ROC (Joel Greenblatt) % is ranked higher than
97% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NYSE:Q: 221.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:Q' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 209.76  Med: 267.89 Max: 338.36
Current: 221.96
209.76
338.36
3-Year Revenue Growth Rate 4.30
NYSE:Q's 3-Year Revenue Growth Rate is ranked lower than
53% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NYSE:Q: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:Q' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.4  Med: 4.3 Max: 6.2
Current: 4.3
3.4
6.2
3-Year EBITDA Growth Rate 11.50
NYSE:Q's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NYSE:Q: 11.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:Q' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 2.4  Med: 12.2 Max: 19
Current: 11.5
2.4
19
3-Year EPS without NRI Growth Rate -24.60
NYSE:Q's 3-Year EPS without NRI Growth Rate is ranked lower than
75% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NYSE:Q: -24.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:Q' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.6  Med: 9.55 Max: 26.8
Current: -24.6
-24.6
26.8
GuruFocus has detected 5 Warning Signs with Quintiles IMS Holdings Inc $NYSE:Q.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:Q's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

Q Guru Trades in Q2 2016

John Paulson 164,200 sh (New)
Larry Robbins 1,919,555 sh (New)
Ken Fisher 88,164 sh (+63.07%)
Paul Tudor Jones 37,446 sh (+62.27%)
Joel Greenblatt 350,600 sh (+56.16%)
Vanguard Health Care Fund 2,929,638 sh (+51.61%)
Jim Simons 528,700 sh (-19.91%)
Columbia Wanger 1,010,406 sh (-26.52%)
Ron Baron 371,210 sh (-28.17%)
» More
Q3 2016

Q Guru Trades in Q3 2016

Larry Robbins 3,381,622 sh (+76.17%)
Ken Fisher 126,587 sh (+43.58%)
John Paulson Sold Out
Vanguard Health Care Fund 2,539,738 sh (-13.31%)
Columbia Wanger 836,973 sh (-17.16%)
Ron Baron 300,810 sh (-18.97%)
Joel Greenblatt 241,654 sh (-31.07%)
Jim Simons 242,300 sh (-54.17%)
Paul Tudor Jones 16,149 sh (-56.87%)
» More
Q4 2016

Q Guru Trades in Q4 2016

Larry Robbins 6,927,335 sh (+104.85%)
Vanguard Health Care Fund 4,338,077 sh (+70.81%)
Joel Greenblatt 294,178 sh (+21.74%)
Ken Fisher 134,287 sh (+6.08%)
Jim Simons Sold Out
Paul Tudor Jones 11,600 sh (-28.17%)
Ron Baron 134,776 sh (-55.20%)
Columbia Wanger 268,642 sh (-67.90%)
» More
Q1 2017

Q Guru Trades in Q1 2017

Steve Mandel 5,976,041 sh (New)
Jim Simons 61,557 sh (New)
Steven Cohen 225,600 sh (New)
Columbia Wanger Sold Out
Ron Baron Sold Out
Larry Robbins 6,897,637 sh (-0.43%)
Paul Tudor Jones 9,988 sh (-13.90%)
Ken Fisher 114,787 sh (-14.52%)
Vanguard Health Care Fund 2,298,597 sh (-47.01%)
Joel Greenblatt 89,568 sh (-69.55%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621399    SIC: 8099
Compare:NYSE:A, NYSE:DGX, NAS:IDXX, NYSE:LH, OTCPK:SSMXY, OTCPK:ERFSF, OTCPK:BMXMF, NAS:QGEN, NYSE:PKI, OTCPK:SUVPF, NYSE:BIO.B, NAS:INCR, NAS:DXCM, NAS:ICLR, OTCPK:CZMWF, NAS:PRAH, NYSE:CRL, NAS:VWR, NAS:BRKR, NYSE:ALR » details
Traded in other countries:QTS.Germany,
Headquarter Location:USA
Quintiles IMS Holdings Inc is an information and technology company. The Company offers professional services, information technology and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries.

QuintilesIMS formed from the merger of the healthcare data and analytics of IMS Health with the global contract research organization powerhouse of Quintiles. The CRO segment focuses primarily on providing outsourced phase 2-4 clinical trials for pharmaceutical, device, and diagnostic companies. The IMS segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers.

Ratios

vs
industry
vs
history
PE Ratio 537.64
Q's PE Ratio is ranked lower than
93% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. Q: 537.64 )
Ranked among companies with meaningful PE Ratio only.
Q' s PE Ratio Range Over the Past 10 Years
Min: 18.67  Med: 24.43 Max: 538.08
Current: 537.64
18.67
538.08
Forward PE Ratio 19.16
Q's Forward PE Ratio is ranked higher than
68% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. Q: 19.16 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 537.64
Q's PE Ratio without NRI is ranked lower than
93% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. Q: 537.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
Q' s PE Ratio without NRI Range Over the Past 10 Years
Min: 18.67  Med: 24.43 Max: 538.08
Current: 537.64
18.67
538.08
Price-to-Owner-Earnings 40.03
Q's Price-to-Owner-Earnings is ranked higher than
64% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. Q: 40.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Q' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.44  Med: 20.28 Max: 40.06
Current: 40.03
15.44
40.06
PB Ratio 2.62
Q's PB Ratio is ranked higher than
71% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. Q: 2.62 )
Ranked among companies with meaningful PB Ratio only.
Q' s PB Ratio Range Over the Past 10 Years
Min: 2.13  Med: 2.36 Max: 2.62
Current: 2.62
2.13
2.62
PS Ratio 1.91
Q's PS Ratio is ranked higher than
81% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. Q: 1.91 )
Ranked among companies with meaningful PS Ratio only.
Q' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.44 Max: 1.91
Current: 1.91
1.02
1.91
Price-to-Free-Cash-Flow 25.18
Q's Price-to-Free-Cash-Flow is ranked higher than
75% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. Q: 25.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Q' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.11  Med: 21.5 Max: 35.27
Current: 25.18
14.11
35.27
Price-to-Operating-Cash-Flow 19.04
Q's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. Q: 19.04 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Q' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.19  Med: 17.16 Max: 26.1
Current: 19.04
12.19
26.1
EV-to-EBIT 43.48
Q's EV-to-EBIT is ranked lower than
80% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. Q: 43.48 )
Ranked among companies with meaningful EV-to-EBIT only.
Q' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.7  Med: 16.6 Max: 44.9
Current: 43.48
13.7
44.9
EV-to-EBITDA 24.16
Q's EV-to-EBITDA is ranked lower than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. Q: 24.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
Q' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.5  Med: 13.6 Max: 28.4
Current: 24.16
11.5
28.4
PEG Ratio 39.26
Q's PEG Ratio is ranked lower than
86% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. Q: 39.26 )
Ranked among companies with meaningful PEG Ratio only.
Q' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 39.6
Current: 39.26
0
39.6
Current Ratio 1.20
Q's Current Ratio is ranked lower than
83% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. Q: 1.20 )
Ranked among companies with meaningful Current Ratio only.
Q' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.4 Max: 1.65
Current: 1.2
1.15
1.65
Quick Ratio 1.20
Q's Quick Ratio is ranked lower than
77% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. Q: 1.20 )
Ranked among companies with meaningful Quick Ratio only.
Q' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.4 Max: 1.65
Current: 1.2
1.15
1.65
Days Sales Outstanding 48.62
Q's Days Sales Outstanding is ranked higher than
64% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. Q: 48.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
Q' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.13  Med: 29.51 Max: 52.96
Current: 48.62
25.13
52.96
Days Payable 17.58
Q's Days Payable is ranked lower than
84% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. Q: 17.58 )
Ranked among companies with meaningful Days Payable only.
Q' s Days Payable Range Over the Past 10 Years
Min: 8.02  Med: 9.9 Max: 19.21
Current: 17.58
8.02
19.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.20
Q's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. Q: -24.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
Q' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.2  Med: -2.45 Max: -0.4
Current: -24.2
-24.2
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.35
Q's Price-to-Median-PS-Value is ranked lower than
52% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. Q: 1.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Q' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.97 Max: 1.35
Current: 1.35
0
1.35
Earnings Yield (Greenblatt) % 2.31
Q's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. Q: 2.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
Q' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 6 Max: 7.3
Current: 2.31
2.2
7.3

More Statistics

Revenue (TTM) (Mil) $7,710
EPS (TTM) $ 0.16
Beta0.60
Short Percentage of Float7.68%
52-Week Range $61.21 - 86.11
Shares Outstanding (Mil)219.39

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,033 8,540 8,895
EPS ($) 4.49 5.16 5.72
EPS without NRI ($) 4.49 5.16 5.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.74%
Dividends per Share ($)
» More Articles for Q

Headlines

Articles On GuruFocus.com
Parexel Investors: Swimming With the Whales Mar 03 2017 
The Big 3: Larry Robbins' Top 2nd-Quarter Buys Aug 16 2016 
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 

More From Other Websites
QuintilesIMS Announces Pricing of Secondary Public Offering May 25 2017
QuintilesIMS Announces Launch of Secondary Public Offering, Repurchase of Common Stock and Increase... May 24 2017
Biopharmaceutical Services Stock Continues To Test New Buy Zone May 12 2017
Hedge fund manager Robbins likes 3 stocks that are breaking out of 'regulatory purgatory' May 08 2017
Edited Transcript of Q.N earnings conference call or presentation 3-May-17 1:00pm GMT May 05 2017
QuintilesIMS Institute Study: U.S. Drug Spending Growth of 4.8 Percent in 2016 May 05 2017
Quintiles IMS Holdings Starts 2017 Strong May 04 2017
Quintiles beats 1Q profit forecasts May 03 2017
QuintilesIMS Reports First-Quarter 2017 Results and Raises Full-Year 2017 Adjusted Diluted EPS... May 03 2017
QuintilesIMS in Deal to Use Salesforce.com’s Cloud Technology Apr 24 2017
QuintilesIMS Announces Alliance with Salesforce to Build Next Generation Solutions for Life Sciences... Apr 24 2017
QuintilesIMS to Announce First-Quarter 2017 Results on May 3, 2017 Apr 19 2017
Quintiles IMS Holdings, Inc. breached its 50 day moving average in a Bearish Manner : Q-US : April... Apr 06 2017
Triangle CROs among best to work with, says survey Apr 03 2017
9 New Stocks in the Wide Moat Focus Mar 28 2017
Quintiles IMS Holdings, Inc. breached its 50 day moving average in a Bullish Manner : Q-US : March... Mar 27 2017
Winning Stock Picks from the Top 5 Industries with the Biggest Job Growth Mar 14 2017
Parexel Investors: Swimming With the Whales Mar 03 2017
Post Earnings Coverage as Quintiles IMS' Q4 Bottom-line Beat Market Estimates Mar 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)